Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoVaccine to combine proprietary antigens with DepoVax delivery platform to develop cancer vaccine
Subscribe to our email newsletter
ImmunoVaccine (IVT) has entered into an agreement to exclusively license seven cancer antigens from Immunotope.
The company said that these antigens will specifically target breast, ovarian and prostate cancers. IVT will combine the proprietary antigens with its DepoVax delivery platform to develop DPX-0907, a therapeutic cancer vaccine.
Under the license agreement, IVT has agreed to an up-front payment, as well as future milestone payments and royalties to Immunotope for use of the antigens. This licensing agreement replaces the acquisition of Immunotope agreement.
Randal Chase, president and CEO of IVT, said: “This licensing agreement significantly advances our cancer immunotherapy capabilities and represents our continued commitment to developing our DepoVax technology within a robust clinical trial program.